Prenetics Global Limited (NASDAQ:PRE - Get Free Report) was the target of a large increase in short interest in February. As of February 15th, there was short interest totalling 39,800 shares, an increase of 22.1% from the January 31st total of 32,600 shares. Approximately 0.5% of the company's shares are sold short. Based on an average daily trading volume, of 14,100 shares, the short-interest ratio is currently 2.8 days.
Prenetics Global Stock Performance
Prenetics Global stock traded down $0.25 during midday trading on Monday, reaching $4.51. The stock had a trading volume of 14,657 shares, compared to its average volume of 13,963. The firm's fifty day simple moving average is $5.45 and its 200-day simple moving average is $4.99. The stock has a market capitalization of $54.98 million, a P/E ratio of -1.13 and a beta of -0.31. Prenetics Global has a 1-year low of $2.85 and a 1-year high of $7.84.
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in Prenetics Global stock. Quinn Opportunity Partners LLC acquired a new stake in Prenetics Global Limited (NASDAQ:PRE - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 12,339 shares of the company's stock, valued at approximately $72,000. Quinn Opportunity Partners LLC owned approximately 0.10% of Prenetics Global at the end of the most recent reporting period. 25.01% of the stock is owned by hedge funds and other institutional investors.
Analyst Upgrades and Downgrades
Separately, Cantor Fitzgerald reiterated an "overweight" rating and set a $9.00 price objective on shares of Prenetics Global in a report on Thursday, January 16th.
View Our Latest Research Report on Prenetics Global
Prenetics Global Company Profile
(
Get Free Report)
Prenetics Global Limited, a genomics-driven health sciences company, engages in revolutionizing prevention, early detection, and treatment. It offers CircleDNA, a prevention arm that uses whole exome sequencing to offer comprehensive consumer DNA test. The company also, through its joint venture, Insighta, engages in pioneering multi-cancer early detection technologies.
See Also
Before you consider Prenetics Global, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Prenetics Global wasn't on the list.
While Prenetics Global currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
